RELMADA THERAPEUTICS, INC.·4

Sep 11, 5:47 PM ET

TRAVERSA SERGIO 4

4 · RELMADA THERAPEUTICS, INC. · Filed Sep 11, 2024

Insider Transaction Report

Form 4
Period: 2024-09-09
TRAVERSA SERGIO
DirectorChief Executive Officer
Transactions
  • Purchase

    Common Stock

    2024-09-11$2.99/sh+51,407$153,707384,024 total
  • Purchase

    Common Stock

    2024-09-09$2.71/sh+55,579$150,619299,603 total
  • Purchase

    Common Stock

    2024-09-10$2.75/sh+33,014$90,789332,617 total
Footnotes (4)
  • [F1]The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.
  • [F2]Purchase prices range from $2.51 to $2.85 per share, inclusive.
  • [F3]Purchase prices range from $2.73 to $2.80 per share, inclusive.
  • [F4]Purchase prices range from $2.84 to $3.05 per share, inclusive.

Documents

1 file
  • 4
    ownership.xmlPrimary

    OWNERSHIP DOCUMENT